Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL

Background TRAIL is considered as a promising anti-cancer agent, because of its ability to induce apoptosis in cancer but not in most normal cells. However, growing evidence exist that many cancer cells are resistant to its apoptotic effects. SCLC is a typical example of tumor entity where TRAIL monotherapy is not efficient.